Scoreflex NC Scoring PTCA Catheter
OrbusNeich Medical (Shenzhen) Co., Ltd. · Decision date Oct 29, 2025
What did the FDA decide?
FDA records P200041/S009 as a supplement to PMA P200041, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Oct 29, 2025.
FDA approval order statement
optimization of manufacturing parameters, adjustments to routine sterility testing and process automation
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 29, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P200041/S009
- Regulatory pathway
- PMA supplement
- Product code
- NWX
- Decision code
- OK30
- Decision date
- Oct 29, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Catheter, percutaneous transluminal coronary angioplasty (ptca), cutting/scoring.
- Product code
- NWX
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P200041/S009 received
Application receipt date recorded by FDA.
P200041/S009 · FDA decision
30-Day Notice
P200041/S005 · Related supplement
Scoreflex NC Scoring PTCA Catheter
Timeline entries are records held by MedtechLedger for P200041. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200041
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Scoreflex NC Scoring PTCA CatheterP200041/S005 | OrbusNeich Medical (Shenzhen) Co., Ltd. | PMA supplement | Jul 31, 2026 | FDA |
Explore the linked device profile
Other records with product code NWX
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Lacrosse NSE ALPHA Coronary Dilatation CatheterP230026/S003 | NIPRO VASCULAR CORPORATION (formerly Goodman Co., Ltd.) | PMA supplement | Jul 22, 2026 | FDA |
Lacrosse NSE ALPHA Coronary Dilatation CatheterP230026/S004 | NIPRO VASCULAR CORPORATION (formerly Goodman Co., Ltd.) | PMA supplement | Jul 22, 2026 | FDA |
Lacrosse NSE ALPHA Coronary Dilatation CatheterP230026/S005 | NIPRO VASCULAR CORPORATION (formerly Goodman Co., Ltd.) | PMA supplement | Jul 22, 2026 | FDA |
WOLVERINE Coronary Cutting BalloonP950020/S148 | Boston Scientific Corp | PMA supplement | Jan 27, 2026 | FDA |
WOLVERINE Coronary Cutting BalloonP950020/S147 | Boston Scientific Corp | PMA supplement | Dec 1, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
OrbusNeich Medical (Shenzhen) Co., Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- #1 Jinkui Rd., Futian Free Trade Zone, Shenzhen, 518038
Sources and methodology
- Original FDA record: P200041/S009
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

